IgA nephropathy

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Chugai Pharma has reached a deal to buy Renalys Pharma, a company set up to bring therapies developed elsewhere to markets in Asia.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

NICE relents and backs drug for IgAN from CSL Vifor

Thousands of people living with rare kidney disease IgAN in the UK will soon be able to access a new oral treatment from CSL Vifor.

News

Novartis gets FDA nod for second of three IgAN drugs

Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.

News

Biogen shows its IgAN hand with felzartamab data

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class t

Otsuka joins IgAN market with Voyxact approval in US

Chugai buys 'Asia lag' firm Renalys for $98m upfront

Otsuka, Vera stake their claims to IgAN treatment

NICE relents and backs drug for IgAN from CSL Vifor

Novartis gets FDA nod for second of three IgAN drugs

Biogen shows its IgAN hand with felzartamab data

On digital twins in rare disease research, with Piet van der...

How to meet your physicians where they are online

IgA nephropathy

Editor's Picks